Spexis AG

SW:SPEX Switzerland Biotechnology
Market Cap
$317.64 Billion
CHF290.86 Billion CHF
Market Cap Rank
#31883 Global
#122 in Switzerland
Share Price
CHF4298.50
Change (1 day)
-4.87%
52-Week Range
CHF0.01 - CHF4564.00
All Time High
CHF4564.00
Categories
Companies in Switzerland Biotechnology
About

Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase … Read more

Spexis AG (SPEX) - Net Assets

Latest net assets as of December 2023: CHF2.29 Million CHF

Based on the latest financial reports, Spexis AG (SPEX) has net assets worth CHF2.29 Million CHF as of December 2023.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF16.78 Million) and total liabilities (CHF14.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF2.29 Million
% of Total Assets 13.64%
Annual Growth Rate -54.86%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 84.73

Spexis AG - Net Assets Trend (2019–2023)

This chart illustrates how Spexis AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Spexis AG (2019–2023)

The table below shows the annual net assets of Spexis AG from 2019 to 2023.

Year Net Assets Change
2023-12-31 CHF2.29 Million -88.21%
2022-12-31 CHF19.40 Million -35.81%
2021-12-31 CHF30.22 Million +124.00%
2020-12-31 CHF13.49 Million -75.52%
2019-12-31 CHF55.11 Million --

Equity Component Analysis

This analysis shows how different components contribute to Spexis AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4217182000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Other Components CHF55.49 Million 2425.43%
Total Equity CHF2.29 Million 100.00%

Spexis AG Competitors by Market Cap

The table below lists competitors of Spexis AG ranked by their market capitalization.

Company Market Cap
Trilogiq
PA:ALTRI
 		$4.21 Million
NICO Resources Limited
OTCGREY:NICOF
 		$4.22 Million
Adventa Bhd
KLSE:7191
 		$4.22 Million
INDUSTRIAL MINERALS LTD
F:9ED
 		$4.22 Million
Manaksia Aluminium Company Limited
NSE:MANAKALUCO
 		$4.21 Million
Cruz Cobalt Corp
PINK:BKTPF
 		$4.21 Million
Lovable Lingerie Limited
NSE:LOVABLE
 		$4.21 Million
Taiga Motors Corporation
PINK:TAIMF
 		$4.21 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Spexis AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from 19,401,979 to 2,287,822, a change of -17,114,157 (-88.2%).
  • Net loss of 19,618,868 reduced equity.
  • Other factors increased equity by 2,504,711.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income CHF-19.62 Million -857.53%
Other Changes CHF2.50 Million +109.48%
Total Change CHF- -88.21%

Book Value vs Market Value Analysis

This analysis compares Spexis AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 110786.10x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 862.95x to 110786.10x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 CHF4.98 CHF4298.50 x
2020-12-31 CHF1.20 CHF4298.50 x
2021-12-31 CHF0.63 CHF4298.50 x
2022-12-31 CHF0.41 CHF4298.50 x
2023-12-31 CHF0.04 CHF4298.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Spexis AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -857.53%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 7.33x
  • Recent ROE (-857.53%) is below the historical average (-288.61%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 -117.35% -644136.53% 0.00x 1.68x CHF-70.18 Million
2020 -333.14% -314.82% 0.31x 3.47x CHF-46.30 Million
2021 -39.38% 0.00% 0.00x 1.66x CHF-14.87 Million
2022 -95.62% 0.00% 0.00x 1.54x CHF-20.49 Million
2023 -857.53% 0.00% 0.00x 7.33x CHF-19.85 Million

Industry Comparison

This section compares Spexis AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $739,128,343
  • Average return on equity (ROE) among peers: 2.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Spexis AG (SPEX) CHF2.29 Million -117.35% 6.33x $4.21 Million
BB Biotech AG (BION) $1.91 Billion 10.59% 0.00x $482.21K
Newron Pharmaceuticals SpA (NWRN) $67.72 Million -7.80% 0.08x $319.05 Million
Xlife Sciences AG (XLS) $235.23 Million 6.08% 1.08x $72.54 Million